Document title |
Last web update |
In force from |
---|---|---|
Pandemic COVID-19 Vaccine (Non-Replicating Adenovirus-Vectored Vaccine) (full version) |
20/04/21 | 01/05/21 |
Pandemic COVID-19 Vaccine (mRNA Vaccine) (full version) |
06/04/21 |
01/05/21 |
Pandemic COVID-19 Vaccine (Recombinant Spike protein) (full version) |
08/03/22 | 21/03/22 |
Pandemic COVID-19 Vaccine, Inactivated (section 2 only) | 04/05/22 | 04/05/22 |
The availability of the "section 2 only" guideline, with the list of tests to be performed by OMCLs for OCABR, at an early stage helps to anticipate the launch of the vaccines and allows OMCLs and manufacturers to take the necessary steps for OCABR thus preventing delays in availability while still ensuring their quality and safety. As soon as possible, a full guideline including model protocols is adopted by the network to provide a codified framework for ongoing OCABR.